Jan 22, 2025 · Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to making a world of difference in cancer care. Through research, education, and promotion of the highest-quality, equitable patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy.

May 15, 2024 · Brain metastases (BMs) occur in 20%-40% of patients with breast cancer during the course of their disease. 1 BMs from solid tumors contribute significantly to morbidity and/or mortality, with about 200,000 patients—10% of all patients with cancer—diagnosed each year in the United States. 2 Notably, Breast Cancer BMs (BCBM) represents second most common …

Jan 10, 2024 · Clinicians should recommend treatment according to menopausal status, pathological and biomarker features when quality results are available. In first-line, for hormone receptor (HR)–positive MBC, when a non-steroidal aromatase inhibitor and CDK 4/6 inhibitor combination is unavailable, use hormonal therapy alone.

Apr 8, 2022 · A monoclonal gammopathy is a laboratory-based finding that is being increasingly recognized in the aging population. Until recently, the incidence of monoclonal gammopathy of undetermined significance (MGUS) was based on studies from Olmsted County, Minnesota, and from Scandinavian health records, indicating an incidence of approximately 1%. 1 The majority …

Jan 13, 2020 · First released in 2010, the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) estrogen receptor (ER) and progesterone receptor (PgR) testing guideline is aimed at improving the analytic performance and diagnostic accuracy of ER and PgR testing and their clinical utility as biomarkers for the management of women with primary …

In the United States, it is estimated that between 8% and 10% of patients with cancer will develop brain metastases representing approximately 200,000 new patients with brain metastases every year. 1 The point prevalence of brain metastases on initial diagnosis varies widely between different cancer histologies. For example, the incidence proportion of patients with metastatic …

Jul 14, 2020 · The identified data reconfirmed that no agents are recommended for the prevention of CIPN. The use of acetyl-l-carnitine for the prevention of CIPN in patients with cancer should be discouraged.Furthermore, clinicians should assess the appropriateness of dose delaying, dose reduction, substitutions, or stopping chemotherapy in patients who develop intolerable …

Immunotherapy has revolutionized the treatment of many different types of cancers. Immune checkpoint inhibitors (ICPis) targeting cytotoxic T-lymphocyte–associated antigen-4 (CTLA-4), programmed cell death-1 (PD-1), and PD ligand 1 (PD-L1) work by preventing the receptors and ligands from binding to each other, thereby disrupting signaling so that T cells can recognize …

In the United States, the Controlled Substance Act renders cannabis with >0.3% delta-9-tetrahydrocannabinol (THC) schedule I. This status signifies that cannabis has no accepted medical use and a high potential for abuse. 20 The schedule I designation creates frequent conflicts between federal and state laws, as 38 states now allow medical cannabis use by …

Total neoadjuvant therapy (TNT) is now recognized as the preferred standard for the treatment of locally advanced rectal cancer. 1 Using this approach, all nonsurgical interventions, including multiagent chemotherapy and concurrent chemoradiotherapy (CRT), are administered before surgical resection or the decision on nonoperative management is made. . Multiagent systemic …